DE602004013135D1 - Verfahren für die Diagnose von schwerkranken Patienten - Google Patents

Verfahren für die Diagnose von schwerkranken Patienten

Info

Publication number
DE602004013135D1
DE602004013135D1 DE602004013135T DE602004013135T DE602004013135D1 DE 602004013135 D1 DE602004013135 D1 DE 602004013135D1 DE 602004013135 T DE602004013135 T DE 602004013135T DE 602004013135 T DE602004013135 T DE 602004013135T DE 602004013135 D1 DE602004013135 D1 DE 602004013135D1
Authority
DE
Germany
Prior art keywords
pro
critically ill
ill patients
diagnosis
endothelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004013135T
Other languages
English (en)
Other versions
DE602004013135T2 (de
Inventor
Andreas Dr Bergmann
Joachim Dr Struck
Nils G Morgenthaler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of DE602004013135D1 publication Critical patent/DE602004013135D1/de
Application granted granted Critical
Publication of DE602004013135T2 publication Critical patent/DE602004013135T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE602004013135T 2004-07-22 2004-08-13 Verfahren für die Diagnose von schwerkranken Patienten Active DE602004013135T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017403 2004-07-22
EP04017403 2004-07-22

Publications (2)

Publication Number Publication Date
DE602004013135D1 true DE602004013135D1 (de) 2008-05-29
DE602004013135T2 DE602004013135T2 (de) 2009-07-02

Family

ID=34993078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013135T Active DE602004013135T2 (de) 2004-07-22 2004-08-13 Verfahren für die Diagnose von schwerkranken Patienten

Country Status (4)

Country Link
EP (1) EP1619505B1 (de)
AT (1) ATE392623T1 (de)
DE (1) DE602004013135T2 (de)
ES (1) ES2300681T3 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
US9829494B2 (en) * 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US8906857B2 (en) 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (de) 2006-04-04 2013-04-24 Singulex Inc Verfahren und zusammensetzungen zur hochempfindlichen analyse von markern und zur detektion von molekülen
DE102006034142A1 (de) 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur Steuerung der Therapie von Patienten mit Herzinsuffizienz anhand der vitro Bestimmung von Schwellenwerten von vasoaktiven Peptiden
DE102006052916A1 (de) * 2006-11-08 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
DE102006060835A1 (de) * 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP
DE102007021443A1 (de) * 2007-05-08 2008-11-13 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels NT-proET-1
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
ES2431358T3 (es) * 2008-11-11 2013-11-26 B.R.A.H.M.S Gmbh Pronóstico y evaluación del riesgo en pacientes que padecen insuficiencia cardíaca mediante la determinación de la concentración de ADM
EP2440936A4 (de) 2009-06-08 2013-03-13 Singulex Inc Hochempfindliche biomarkertafeln
EP3032261B1 (de) * 2010-06-18 2018-05-23 B.R.A.H.M.S GmbH Mr-pro-amd für die vorhersage der inzidenz eines karzinoms in mänlichen patienten unter 57.9 jahre.
EP2583106A1 (de) * 2010-06-18 2013-04-24 Cézanne S.A.S. Marker zur prognose und risikobeurteilung von schwangerschaftsbedingter hypertonie und präeklampsie
EP3497451A1 (de) * 2016-08-09 2019-06-19 B.R.A.H.M.S GmbH Histone und/oder proadm als marker zur anzeige eines unerwünschten ereignisses
JP7270912B2 (ja) * 2017-05-22 2023-05-11 東ソー株式会社 アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
ES2909399T3 (es) * 2017-09-13 2022-05-06 Brahms Gmbh Proadrenomedulina como marcador de niveles anormales de plaquetas
EP3608673A1 (de) * 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm zur prognose des risikos einer erkrankung, die einen krankenhausaufenthalt bei patienten mit symptomen einer infektionskrankheit erfordert

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613804B2 (en) * 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
DE19847690A1 (de) * 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen

Also Published As

Publication number Publication date
DE602004013135T2 (de) 2009-07-02
EP1619505B1 (de) 2008-04-16
EP1619505A3 (de) 2006-02-22
ES2300681T3 (es) 2008-06-16
ATE392623T1 (de) 2008-05-15
EP1619505A2 (de) 2006-01-25

Similar Documents

Publication Publication Date Title
DE602004013135D1 (de) Verfahren für die Diagnose von schwerkranken Patienten
ATE554395T1 (de) Diagnose septischer komplikationen
Moore et al. The role of veterinary team effectiveness in job satisfaction and burnout in companion animal veterinary clinics
Bjork et al. Obturator hernia.
HK1183707A1 (en) Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease (pct)
DE602005018264D1 (de) Künstliches blutgefäss
DE602006019262D1 (de) QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN
CY1119867T1 (el) Αναστολεις vap-1 για χρηση στη θεραπεια ινωτικων καταστασεων
TW200600778A (en) An analyte measuring system which prevents the reuse of a test strip
WO2007044860A3 (en) Diabetes-associated markers and methods of use thereof
WO2006086019A3 (en) Methods of treating diabetes
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
WO2004097429A3 (en) Apociii and the treatmentand diagnosis of diabetes
WO2008132464A3 (en) Mek5 and related proteins as biomarkers of neurodegenerative diseases
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
ATE441107T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
ATE354097T1 (de) Verfahren zur diagnose von leberfibrose.
ATE411771T1 (de) Selektive exposition von miniatursonden mit integrierten sensorarrays für kontinuierlichen in-vivo diagnosis
MX2021015445A (es) Ensayo de quimioluminiscencia a base de oxidasa de leucocitos fagocitica en sangre entera y en fluidos corporales aplicables a las pruebas de diagnostico de punto de cuidado (poc) la medicion de punto de cuidado (poc) de la funcion neutrofila absoluta (anf).
Chudek et al. Coping with overweight strategies, self-esteem and body-esteem in the context of transactional analysis
Edwards et al. Realignment of tobacco control services—will it be sufficient to achieve the nation’s Smokefree 2025 Goal?
Deldar et al. Soft tissue coverage of lower extremity defects: pearls and pitfalls in the chronic wound population
AR051870A1 (es) Metodos para el diagnostico y tratamiento de pacientes con enfermedad critica, y el uso de endotelina y agonistas de endotelina con actividad vasoconstrictora en la preparacion de medicamentos para el tratamiento de pacientes con enfermedad critica
Forrest et al. Breaking the cycle of pain in interstitial cystitis/painful bladder syndrome: toward standardization of early diagnosis and treatment: consensus panel recommendations
Destri et al. Stress of routine follow-up in colorectal cancer operated patients

Legal Events

Date Code Title Description
8364 No opposition during term of opposition